Osteopore Ltd.
AASX:OSX0.00
AUD
0.00
(0.00%)
ISIN
AU0000053324
Return %
Stock
S&P 500
1Y
-63.64
14.20
3Y
-97.13
81.12
5Y
-99.44
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Yu Jing Lim
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 2 Tukang Innovation Grove #09-06/07 Perth WA Australia 618305
- IPO Date
- Sep 19, 2019
- Website
- osteopore.com
- Similar Companies
- Business
- Osteopore Limited is a medical technology company specializing in regenerative medicine, primarily developing and commercializing 3D-printed bioresorbable implants that promote natural bone regeneration. Its product portfolio includes osteoplug implants for filling bone voids such as burr holes; osteoplug-C with access for shunts or drainage catheters; osteomesh for covering defects such as orbital floor reconstruction or craniosynostosis; and patient-specific craniofacial implants for cranioplasty and reconstruction. These implants are designed using biomimetic microarchitecture and bioresorbable polymers that degrade naturally as new bone tissue regenerates, reducing complications associated with permanent implants. Osteopore's products serve surgical applications in neurosurgery, craniofacial, and orthopedic sectors and are used across Asia, Europe, Australia, and the Americas, with regulatory approvals in over 20 countries and regions. The company was founded in 2011 and is headquartered in Singapore. Recent major developments include Osteopore's acquisition of multiple medical distribution businesses responsible for about 40-45% of its global sales, transitioning the company toward a vertically integrated business model that controls manufacturing, marketing, and direct sales channels, which is expected to enhance revenue and margins. Osteopore also secured a $20 million capital raise via convertible notes in early 2025, aimed at funding product development, global expansion, and financial restructuring. The company established strategic partnerships, including a collaboration with Accelerate Technologies Pte Ltd to license advanced bioactive technology for faster bone and tissue regeneration and a distribution agreement to expand its orthopedic product presence in Singapore. These initiatives support Osteopore's growth in regenerative medicine by advancing innovation, commercial expansion, and financial stability. Osteopore operates within the regenerative medicine and medical devices industry with a focus on implantable devices that leverage tissue engineering and 3D printing technology. Its target markets include hospitals, surgeons, and healthcare providers requiring advanced solutions for bone repair and reconstruction. The company's strategic efforts underline its commitment to maintaining technology leadership, commercial growth, and shareholder value through ongoing innovation and market penetration. Osteopore is listed on the Australian Securities Exchange under ticker OSX.AX.